Search

Your search keyword '"van der Veldt, Astrid A. M."' showing total 409 results
Start Over Author "van der Veldt, Astrid A. M."
409 results on '"van der Veldt, Astrid A. M."'

1. Safe Stop IPI-NIVO trial: early discontinuation of nivolumab upon achieving a complete or partial response in patients with irresectable stage III or metastatic melanoma treated with first-line ipilimumab-nivolumab – study protocol

Author

Janssen, J. C., van Dijk, B., de Joode, K., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers-Sonderen, M. J., van den Eertwegh, A. J. M., de Groot, J. W. B., Jalving, M., de Jonge, M. J. A., Joosse, A., Kapiteijn, E., Kamphuis-Huismans, A. M., Naipal, K. A. T., Piersma, D., Rikhof, B., Westgeest, H. M., Vreugdenhil, G., Oomen-de Hoop, E., Mulder, E. E. A. P., and van der Veldt, Astrid A. M.

Published
2024
Full Text
View/download PDF

2. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma

Author

Leek, Lindsay V. M., Notohardjo, Jessica C. L., de Joode, Karlijn, Velker, Eline L., Haanen, John B. A. G., Suijkerbuijk, Karijn P. M., Aarts, Maureen J. B., de Groot, Jan Willem B., Kapiteijn, Ellen, van den Berkmortel, Franchette W. P. J., Westgeest, Hans M., de Gruijl, Tanja D., Retel, Valesca P., Cuppen, Edwin, van der Veldt, Astrid A. M., Labots, Mariette, Voest, Emile E., van de Haar, Joris, and van den Eertwegh, Alfons J. M.

Published
2024
Full Text
View/download PDF

3. Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer

Author

Rijnders, Maud, Nakauma-González, J. Alberto, Robbrecht, Debbie G. J., Gil-Jimenez, Alberto, Balcioglu, Hayri E., Oostvogels, Astrid A. M., Aarts, Maureen J. B., Boormans, Joost L., Hamberg, Paul, van der Heijden, Michiel S., Szabados, Bernadett E., van Leenders, Geert J. L. H., Mehra, Niven, Voortman, Jens, Westgeest, Hans M., de Wit, Ronald, van der Veldt, Astrid A. M., Debets, Reno, and Lolkema, Martijn P.

Published
2024
Full Text
View/download PDF

6. Reproducible radiomics through automated machine learning validated on twelve clinical applications

Author

Starmans, Martijn P. A., van der Voort, Sebastian R., Phil, Thomas, Timbergen, Milea J. M., Vos, Melissa, Padmos, Guillaume A., Kessels, Wouter, Hanff, David, Grunhagen, Dirk J., Verhoef, Cornelis, Sleijfer, Stefan, Bent, Martin J. van den, Smits, Marion, Dwarkasing, Roy S., Els, Christopher J., Fiduzi, Federico, van Leenders, Geert J. L. H., Blazevic, Anela, Hofland, Johannes, Brabander, Tessa, van Gils, Renza A. H., Franssen, Gaston J. H., Feelders, Richard A., de Herder, Wouter W., Buisman, Florian E., Willemssen, Francois E. J. A., Koerkamp, Bas Groot, Angus, Lindsay, van der Veldt, Astrid A. M., Rajicic, Ana, Odink, Arlette E., Deen, Mitchell, T., Jose M. Castillo, Veenland, Jifke, Schoots, Ivo, Renckens, Michel, Doukas, Michail, de Man, Rob A., IJzermans, Jan N. M., Miclea, Razvan L., Vermeulen, Peter B., Bron, Esther E., Thomeer, Maarten G., Visser, Jacob J., Niessen, Wiro J., and Klein, Stefan

Subjects
Electrical Engineering and Systems Science - Image and Video Processing, Computer Science - Computer Vision and Pattern Recognition
Abstract

Radiomics uses quantitative medical imaging features to predict clinical outcomes. Currently, in a new clinical application, finding the optimal radiomics method out of the wide range of available options has to be done manually through a heuristic trial-and-error process. In this study we propose a framework for automatically optimizing the construction of radiomics workflows per application. To this end, we formulate radiomics as a modular workflow and include a large collection of common algorithms for each component. To optimize the workflow per application, we employ automated machine learning using a random search and ensembling. We evaluate our method in twelve different clinical applications, resulting in the following area under the curves: 1) liposarcoma (0.83); 2) desmoid-type fibromatosis (0.82); 3) primary liver tumors (0.80); 4) gastrointestinal stromal tumors (0.77); 5) colorectal liver metastases (0.61); 6) melanoma metastases (0.45); 7) hepatocellular carcinoma (0.75); 8) mesenteric fibrosis (0.80); 9) prostate cancer (0.72); 10) glioma (0.71); 11) Alzheimer's disease (0.87); and 12) head and neck cancer (0.84). We show that our framework has a competitive performance compared human experts, outperforms a radiomics baseline, and performs similar or superior to Bayesian optimization and more advanced ensemble approaches. Concluding, our method fully automatically optimizes the construction of radiomics workflows, thereby streamlining the search for radiomics biomarkers in new applications. To facilitate reproducibility and future research, we publicly release six datasets, the software implementation of our framework, and the code to reproduce this study., Comment: 33 pages, 4 figures, 4 tables, 2 supplementary figures, 3 supplementary table, submitted to Medical Image Analysis; revision

Published
2021

7. Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis

Author

Stassen, Robert C, Maas, Carolien C H M, van der Veldt, Astrid A M, Lo, Serigne N, Saw, Robyn P M, Varey, Alexander H R, Scolyer, Richard A, Long, Georgina V, Thompson, John F, Rutkowski, Piotr, Keilholz, Ulrich, van Akkooi, Alexander C J, Verhoef, Cornelis, van Klaveren, David, and Grünhagen, Dirk J

Published
2024
Full Text
View/download PDF

10. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study

Author

van der Kooij, Monique K., Joosse, Arjen, Suijkerbuijk, Karijn P. M., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Boers-Sonderen, Marye J., van den Eertwegh, Alfonsus J. M., de Groot, Jan Willem B., Haanen, John B. A. G., Hospers, Geke A. P., Piersma, Djura, van Rijn, Rozemarijn S., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Westgeest, Hans M., Wouters, Michel W. J. M., Dekkers, Olaf M., and Kapiteijn, Ellen

Published
2023
Full Text
View/download PDF

12. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Author

Blankenstein, Stephanie A., Bonenkamp, Johannes J., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Blokx, Willeke A. M., Boers-Sonderen, Marye J., van den Eertwegh, Alfons J. M., Franken, Margreet G., de Groot, Jan Willem B., Haanen, John B. A. G., Hospers, Geke A. P., Kapiteijn, Ellen W., van Not, Olivier J., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Westgeest, Hans M., Wouters, Michel W. J. M., and van Akkooi, Alexander C. J.

Published
2023
Full Text
View/download PDF

13. Comprehensive characterization of circulating tumor cells and cell‐free DNA in patients with metastatic melanoma

Author

Bos, Manouk K., primary, Kraan, Jaco, additional, Starmans, Martijn P. A., additional, Helmijr, Jean C. A., additional, Verschoor, Noortje, additional, De Jonge, Maja J. A., additional, Joosse, Arjen, additional, van der Veldt, Astrid A. M., additional, te Boekhorst, Peter A. W., additional, Martens, John W. M., additional, Sleijfer, Stefan, additional, and Wilting, Saskia M., additional

Published
2024
Full Text
View/download PDF

14. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

Author

Reijers, Irene L. M., Menzies, Alexander M., van Akkooi, Alexander C. J., Versluis, Judith M., van den Heuvel, Noëlle M. J., Saw, Robyn P. M., Pennington, Thomas E., Kapiteijn, Ellen, van der Veldt, Astrid A. M., Suijkerbuijk, Karijn P. M., Hospers, Geke A. P., Rozeman, Elisa A., Klop, Willem M. C., van Houdt, Winan J., Sikorska, Karolina, van der Hage, Jos A., Grünhagen, Dirk J., Wouters, Michel W., Witkamp, Arjen J., Zuur, Charlotte L., Lijnsvelt, Judith M., Torres Acosta, Alejandro, Grijpink-Ongering, Lindsay G., Gonzalez, Maria, Jóźwiak, Katarzyna, Bierman, Carolien, Shannon, Kerwin F., Ch’ng, Sydney, Colebatch, Andrew J., Spillane, Andrew J., Haanen, John B. A. G., Rawson, Robert V., van de Wiel, Bart A., van de Poll-Franse, Lonneke V., Scolyer, Richard A., Boekhout, Annelies H., Long, Georgina V., and Blank, Christian U.

Published
2022
Full Text
View/download PDF

16. ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

Author

Blankenstein, Stephanie A., Bonenkamp, Johannes J., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Blokx, Willeke A. M., Boers-Sonderen, Marye J., van den Eertwegh, Alfons J. M., Franken, Margreet G., de Groot, Jan Willem B., Haanen, John B. A. G., Hospers, Geke A. P., Kapiteijn, Ellen W., van Not, Olivier J., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Westgeest, Hans M., Wouters, Michel W. J. M., and van Akkooi, Alexander C. J.

Published
2023
Full Text
View/download PDF

17. The development of brain metastases in patients with different therapeutic strategies for metastatic renal cell cancer.

Author

Derks, Sophie H. A. E., van der Meer, Edgar L., Joosse, Arjen, de Jonge, Maja J. A., Slagter, Cleo, Schouten, Joost W., Hoop, Esther Oomen‐de, Smits, Marion, van den Bent, Martin J., Jongen, Joost L. M., and van der Veldt, Astrid A. M.

Subjects
BRAIN metastasis, NEURAL development, RENAL cancer, CANCER cells, WATCHFUL waiting
Abstract

A diagnosis of brain metastasis (BM) significantly affects quality of life in patients with metastatic renal cell cancer (mRCC). Although systemic treatments have shown efficacy in mRCC, active surveillance (AS) is still commonly used in clinical practice. In this single‐center cohort study, we assessed the impact of different initial treatment strategies for metastatic RCC (mRCC) on the development of BM. All consecutive patients diagnosed with mRCC between 2011 and 2022 were included at the Erasmus MC Cancer Institute, the Netherlands, and a subgroup of patients with BM was selected. In total, 381 patients with mRCC (ECM, BM, or both) were identified. Forty‐six patients had BM of whom 39 had metachronous BM (diagnosed ≥1 month after ECM). Twenty‐five (64.1%) of these 39 patients with metachronous BM had received prior systemic treatment for ECM and 14 (35.9%) patients were treatment naive at BM diagnosis. The median BM‐free survival since ECM diagnosis was significantly longer (p =.02) in previously treated patients (29.0 [IQR 12.6–57.0] months) compared to treatment naive patients (6.8 [IQR 1.0–7.0] months). In conclusion, patients with mRCC who received systemic treatment for ECM prior to BM diagnosis had a longer BM‐free survival as compared to treatment naïve patients. These results emphasize the need for careful evaluation of treatment strategies, and especially AS, for patients with mRCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy.

Author

Gangaev, Anastasia, van Sleen, Yannick, Brandhorst, Nicole, Hoefakker, Kelly, Prajapati, Bimal, Singh, Amrita, Boerma, Annemarie, van der Heiden, Marieke, Oosting, Sjoukje F., van der Veldt, Astrid A. M., Hiltermann, T. Jeroen N., GeurtsvanKessel, Corine H., Dingemans, Anne-Marie C., Smit, Egbert F., de Vries, Elisabeth G. E., Haanen, John B. A. G., Kvistborg, Pia, and van Baarle, Debbie

Abstract

Introduction: Research has confirmed the safety and comparable seroconversion rates following SARS-CoV-2 vaccination in patients with solid cancers. However, the impact of cancer treatment on vaccine-induced T cell responses remains poorly understood. Methods: In this study, we expand on previous findings within the VOICE trial by evaluating the functional and phenotypic composition of mRNA-1273-induced T cell responses in patients with solid tumors undergoing immunotherapy, chemotherapy, or both, compared to individuals without cancer. We conducted an ELISpot analysis on 386 participants to assess spike-specific T cell responses 28 days after full vaccination. Further in-depth characterization of using flow cytometry was performed on a subset of 63 participants to analyze the functional phenotype and differentiation state of spike-specific T cell responses. Results: ELISpot analysis showed robust induction of spike-specific T cell responses across all treatment groups, with response rates ranging from 75% to 80%. Flow cytometry analysis revealed a distinctive cytokine production pattern across cohorts, with CD4 T cells producing IFNγ, TNF, and IL-2, and CD8 T cells producing IFNγ, TNF, and CCL4. Variations were observed in the proportion of monofunctional CD4 T cells producing TNF, particularly higher in individuals without cancer and patients treated with chemotherapy alone, while those treated with immunotherapy or chemoimmunotherapy predominantly produced IFNγ. Despite these differences, polyfunctional spike-specific memory CD4 and CD8 T cell responses were comparable across cohorts. Notably, immunotherapy-treated patients exhibited an expansion of spike-specific CD4 T cells with a terminally differentiated effector memory phenotype. Discussion: These findings demonstrate that systemic treatment in patients with solid tumors does not compromise the quality of polyfunctional mRNA-1273-induced T cell responses. This underscores the importance of COVID-19 vaccination in patients with solid cancers undergoing systemic treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapy

Author

Verver, Danielle, Grünhagen, Dirk J., van Akkooi, Alexander C. J., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., van den Eertwegh, Alfonsus J. M., de Groot, Jan Willem B., Boers-Sonderen, Marye J., Haanen, John B. A. G., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., Tije, Albert J.ten, Vreugdenhil, Gerard, Verhoef, Cornelis, and van der Veldt, Astrid A. M.

Published
2021
Full Text
View/download PDF

20. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial

Author

Oosting, Sjoukje F, van der Veldt, Astrid A M, GeurtsvanKessel, Corine H, Fehrmann, Rudolf S N, van Binnendijk, Rob S, Dingemans, Anne-Marie C, Smit, Egbert F, Hiltermann, T Jeroen N, den Hartog, Gerco, Jalving, Mathilda, Westphal, Tatjana T, Bhattacharya, Arkajyoti, van der Heiden, Marieke, Rimmelzwaan, Guus F, Kvistborg, Pia, Blank, Christian U, Koopmans, Marion P G, Huckriede, Anke L W, van Els, Cecile A C M, Rots, Nynke Y, van Baarle, Debbie, Haanen, John B A G, and de Vries, Elisabeth G E

Published
2021
Full Text
View/download PDF

21. A prediction model for response to immune checkpoint inhibition in advanced melanoma

Author

van Duin, Isabella A. J., primary, Verheijden, Rik J., additional, van Diest, Paul J., additional, Blokx, Willeke A. M., additional, El‐Sharouni, Mary‐Ann, additional, Verhoeff, Joost J. C., additional, Leiner, Tim, additional, van den Eertwegh, Alfonsus J. M., additional, de Groot, Jan Willem B., additional, van Not, Olivier J., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Blank, Christian U., additional, Haanen, John B. A. G., additional, Hospers, Geke A. P., additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, Wouters, Michel W. J. M., additional, Stevense‐den Boer, Marion A. M., additional, Boers‐Sonderen, Marye J., additional, Kapiteijn, Ellen, additional, Suijkerbuijk, Karijn P. M., additional, and Elias, Sjoerd G., additional

Published
2024
Full Text
View/download PDF

22. BRAF/MEK inhibitor rechallenge in advanced melanoma patients

Author

Van Not, Olivier J., primary, van den Eertwegh, Alfons J. M., additional, Haanen, John B., additional, van Rijn, Rozemarijn S., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Blank, Christian U., additional, Boers‐Sonderen, Marye J., additional, de Groot, Jan Willem W. B., additional, Hospers, Geke A. P., additional, Kapiteijn, Ellen, additional, Bloem, Manja, additional, Piersma, Djura, additional, Stevense‐den Boer, Marion, additional, Verheijden, Rik J., additional, van der Veldt, Astrid A. M., additional, Wouters, Michel W. J. M., additional, Blokx, Willeke A. M., additional, and Suijkerbuijk, Karijn P. M., additional

Published
2024
Full Text
View/download PDF

23. Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients

Author

Biewenga, Maaike, van der Kooij, Monique K., Wouters, Michel W. J. M., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan Willem B., Boers-Sonderen, Marye J., Hospers, Geke A. P., Piersma, Djura, van Rijn, Rozemarijn S., Suijkerbuijk, Karijn P. M., ten Tije, Albert J., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, Haanen, John B. A. G., van der Eertwegh, Alfons J. M., van Hoek, Bart, and Kapiteijn, Ellen

Published
2021
Full Text
View/download PDF

24. Adjuvant treatment with anti‐PD‐1 in acral melanoma: A nationwide study.

Author

Bloem, Manja, van Not, Olivier J., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., Blank, Christian U., Blokx, Willeke A. M., Boers‐Sonderen, Marye J., Bonenkamp, Johannes J., de Groot, Jan‐Willem B., Haanen, John B., Hospers, Geke A. P., Kapiteijn, Ellen W., de Meza, Melissa M., Piersma, Djura, van Rijn, Rozemarijn S., Stevense‐den Boer, Marion A. M., van der Veldt, Astrid A. M., Vreugdenhil, Gerard, van den Eertwegh, Alfons J. M., and Suijkerbuijk, Karijn P. M.

Subjects
IMMUNE checkpoint inhibitors, IMMUNOLOGICAL adjuvants, OVERALL survival, REGRESSION analysis, MELANOMA
Abstract

Previous studies demonstrated limited efficacy of immune checkpoint inhibitors in unresectable acral melanoma (AM); it remains unclear how this translates to the adjuvant setting. This study investigates clinical outcomes of acral compared to cutaneous melanoma (CM) patients treated with adjuvant anti‐PD‐1 after complete resection. All stages III–IV AM and CM patients receiving adjuvant anti‐PD‐1 after complete resection between 2018 and 2022 were included from the prospective nationwide Dutch Melanoma Treatment Registry. We analyzed recurrence‐free survival (RFS), distant metastasis‐free survival (DMFS), and overall survival (OS). A multivariable Cox regression analysis of RFS was performed to adjust for potential confounders. We included 1958 (86 AM and 1872 CM) patients. At baseline, AM patients more frequently had KIT mutations, higher disease stages, and Eastern Cooperative Oncology Group Performance Status, and fewer BRAF and NRAS mutations. Median RFS was 14.8 months (95% confidence interval [CI]: 11.5–29.3) in AM and 37.4 months (95% CI: 34.6 to not reached) in CM (p =.002). After correcting for potential confounders, AM remained associated with a higher risk of recurrence (HRadj 1.53; 95% CI: 1.07–2.17; p =.019). Two‐year DMFS tended to be worse for AM than for CM: 64.5% versus 79.7% (p =.050). Two‐year OS was significantly lower in AM (71.5% vs. 84.3%; p =.027). The results of this study suggest a poorer outcome of adjuvant‐treated AM compared to CM. Studies assessing the added value of adjuvant treatment in AM are needed. Future research should investigate alternative treatment strategies to improve outcomes of high‐risk AM. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Detection of Drug-induced Interstitial Lung Disease Caused by Cancer Treatment Using Electronic Nose Exhaled Breath Analysis.

Author

van der Sar, Iris G., Wijsenbeek, Marlies S., Dumoulin, Daphne W., Jager, Agnes, van der Veldt, Astrid A. M., Rossius, Mariska J. P., Dingemans, Anne-Marie C., and Moor, Catharina C.

Subjects
INTERSTITIAL lung diseases, LUNGS, ELECTRONIC noses, DRUG side effects, CANCER treatment, ETIOLOGY of cancer
Abstract

The article examines the rising concern of Drug-induced Interstitial Lung Disease (DIILD) in cancer treatments, emphasizing the urgent need for a noninvasive diagnostic tool. Topics discussed include DIILD incidence rates, challenges in diagnosis, and the potential of electronic nose technology to differentiate patients with DIILD from those without.

Published
2024
Full Text
View/download PDF

26. Real-world Outcomes of Ipilimumab Plus Nivolumab Combination Therapy in a Nation-wide Cohort of Advanced Melanoma Patients in the Netherlands

Author

van Zeijl, Michiel C T, van Breeschoten, Jesper, de Wreede, Liesbeth C, Wouters, Michel W J M, Hilarius, Doranne L, Blank, Christian U, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, de Groot, Jan Willem B, Hospers, Geke A P, Kapiteijn, Ellen, Piersma, Djura, van Rijn, Rozemarijn S, Stevense-den Boer, Marion A, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Boers-Sonderen, Marye J, Suijkerbuijk, Karijn P M, Haanen, John B A G, van den Eertwegh, Alfons J M, Internal medicine, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D), Medical oncology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, CCA - Cancer biology and immunology, Medical Oncology, and Radiology & Nuclear Medicine

Subjects
Pharmacology, Cancer Research, Ipilimumab plus nivolumab, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Immunology, real world, Brain Neoplasms/drug therapy, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], population-based, Nivolumab/therapeutic use, POOLED ANALYSIS, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Melanoma/pathology, SURVIVAL, Immunology and Allergy, Humans, METASTATIC MELANOMA, immunotherapy, Ipilimumab/therapeutic use, Netherlands
Abstract

Item does not contain fulltext In phase III trials, ipilimumab plus nivolumab combination therapy is highly efficacious for advanced melanoma, despite many treatment-related grades 3-4 adverse events. Here, we report real-world safety and survival outcomes of ipilimumab plus nivolumab for advanced melanoma. Patients with advanced melanoma who received first-line ipilimumab plus nivolumab between January 1, 2015 and June 30, 2021 were selected from the Dutch Melanoma Treatment Registry. We evaluated response status at 3, 6, 12, 18, and 24 months. OS and PFS were estimated with the Kaplan-Meier method. Separate analyses were performed for patients with or without brain metastases and for patients who met the inclusion criteria of the Checkmate-067 trial. In total, 709 patients received first-line ipilimumab plus nivolumab. Three hundred sixty (50.7%) patients experienced grade 3-4 adverse events, with 211 of the (58.6%) patients requiring hospital admission. The median treatment duration was 42 days (IQR = 31-139). At 24 months, disease control was achieved in 37% of patients. Median PFS since the start of treatment was 6.6 months (95% CI: 5.3-8.7), and median OS was 28.7 months (95% CI: 20.7-42.2). CheckMate-067 trial-like patients had a 4-year OS of 50% (95% CI: 43-59). Among patients with no asymptomatic or symptomatic brain metastases, the 4-year OS probabilities were 48% (95% CI: 41-55), 45% (95% CI: 35-57), and 32% (95% CI: 23-46). Ipilimumab plus nivolumab can achieve long-term survival in advanced melanoma patients in a real-world setting, including patients not represented in the CheckMate-067 trial. However, the proportion of patients with disease control in the real world is lower compared with clinical trials.

Published
2023

27. Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies

Author

Van Not, Olivier J, van den Eertwegh, Alfons J M, Haanen, John B, van Rijn, Rozemarijn S, Aarts, Maureen J B, van den Berkmortel, Franchette W P J, Blank, Christian U, Boers-Sonderen, Marye J, van Eijs, Mick J M, de Groot, Jan-Willem B, Hospers, Geke A P, Kapiteijn, Ellen, de Meza, Melissa, Piersma, Djura, Stevense-den Boer, Marion, van der Veldt, Astrid A M, Vreugdenhil, Gerard, Wouters, Michel W J M, Suijkerbuijk, Karijn P M, Blokx, Willeke A M, Medical Oncology, Erasmus MC other, Internal medicine, Medical oncology, AII - Cancer immunology, CCA - Cancer Treatment and quality of life, CCA - Cancer biology and immunology, Obstetrics and gynaecology, Amsterdam Reproduction & Development (AR&D), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
Cancer Research, OUTCOMES, Survival, CANCERS, CHRONIC LYMPHOCYTIC-LEUKEMIA, Response, Haematologic malignancy, SOLID TUMORS, Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18], Immune checkpoint inhibitors, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Oncology, CELLS, IMMUNOTHERAPY, Melanoma
Abstract

Background: Patients diagnosed with haematologic malignancies (HMs) have a higher risk of developing subsequent solid tumours, such as melanoma. Patients with HM were mostly excluded from clinical trials but potentially derive less benefit from immune checkpoint inhibitors (ICIs) due to disease-or treatment-related T-or B-cell dysfunction.Methods: All advanced melanoma patients treated with anti-PD-1-based treatment or tar-geted therapy between 2015 and 2021 were included from the prospective nationwide Dutch Melanoma Treatment Registry. Progression-free survival (PFS) and melanoma-specific sur-vival (MSS) were analysed for patients with HM (HM+) and without HM (HM-). A cox model was used to account for confounders associated with PFS and MSS.Results: In total, 4638 advanced melanoma patients received first-line anti-PD-1 mono -therapy (n = 1763), ipilimumab-nivolumab (n = 800), or BRAF(/MEK) inhibitors (n = 2075). Concurrent HMs were present for 46 anti-PD1-treated patients, 11 ipilimumab-nivolumab-treated patients and 43 BRAF(/MEK)-inhibitor-treated patients. In anti-PD-1-treated pa-tients, the median PFS was 2.8 months for HM+ and 9.9 months for HM- (p = 0.01). MSS was 41.2 months for HM+ and 58.1 months for HM- (p = 0.00086). In multivariable analysis, the presence of an HM was significantly associated with higher risk of melanoma progression (HRadj 1.62; 95% confidence interval [95% CI] 1.15-2.29; p = 0.006) and melanoma-related death (HRadj 1.74; 95% CI 1.09-2.78; p = 0.020). Median PFS and MSS for first-line BRAF (/MEK-) inhibitor-treated HM+ and HM- patients were not significantly different.Conclusions: Patients with HM and advanced melanoma show significantly worse melanoma -related outcomes when treated with ICI, but not targeted therapy, compared to patients without HM. Clinicians should be aware of potentially altered effectiveness of ICI in patients with active HM.(c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Published
2023

28. Correlation between Histopathological Prognostic Tumor Characteristics and [ 18 F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer.

Author

Boers, Jorianne, Eisses, Bertha, Zwager, Mieke C., van Geel, Jasper J. L., Bensch, Frederike, de Vries, Erik F. J., Hospers, Geke A. P., Glaudemans, Andor W. J. M., Brouwers, Adrienne H., den Dekker, Martijn A. M., Elias, Sjoerd G., Kuip, Evelien J. M., van Herpen, Carla M. L., Jager, Agnes, van der Veldt, Astrid A. M., Oprea-Lager, Daniela E., de Vries, Elisabeth G. E., van der Vegt, Bert, Menke-van der Houven van Oordt, Willemien C., and Schröder, Carolina P.

Subjects
METASTATIC breast cancer, LOBULAR carcinoma, EPIDERMAL growth factor receptors, METASTASIS, HISTOPATHOLOGY, POSITRON emission tomography
Abstract

Background: In metastatic breast cancer (MBC), [18F]fluorodeoxyglucose positron emission tomography/computed tomography ([18F]FDG-PET/CT) can be used for staging. We evaluated the correlation between BC histopathological characteristics and [18F]FDG uptake in corresponding metastases. Patients and Methods: Patients with non-rapidly progressive MBC of all subtypes prospectively underwent a baseline histological metastasis biopsy and [18F]FDG-PET. Biopsies were assessed for estrogen, progesterone, and human epidermal growth factor receptor 2 (ER, PR, HER2); Ki-67; and histological subtype. [18F]FDG uptake was expressed as maximum standardized uptake value (SUVmax) and results were expressed as geometric means. Results: Of 200 patients, 188 had evaluable metastasis biopsies, and 182 of these contained tumor. HER2 positivity and Ki-67 ≥ 20% were correlated with higher [18F]FDG uptake (estimated geometric mean SUVmax 10.0 and 8.8, respectively; p = 0.0064 and p = 0.014). [18F]FDG uptake was lowest in ER-positive/HER2-negative BC and highest in HER2-positive BC (geometric mean SUVmax 6.8 and 10.0, respectively; p = 0.0058). Although [18F]FDG uptake was lower in invasive lobular carcinoma (n = 31) than invasive carcinoma NST (n = 146) (estimated geometric mean SUVmax 5.8 versus 7.8; p = 0.014), the metastasis detection rate was similar. Conclusions: [18F]FDG-PET is a powerful tool to detect metastases, including invasive lobular carcinoma. Although BC histopathological characteristics are related to [18F]FDG uptake, [18F]FDG-PET and biopsy remain complementary in MBC staging (NCT01957332). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Evaluation of the tolerability and safety of [225Ac]Ac-PSMA-I&T in patients with metastatic prostate cancer: a phase I dose escalation study.

Author

Ling, Sui wai, van der Veldt, Astrid A. M., Konijnenberg, Mark, Segbers, Marcel, Hooijman, Eline, Bruchertseifer, Frank, Morgenstern, Alfred, de Blois, Erik, and Brabander, Tessa

Subjects
*PROSTATE cancer, *PROSTATE cancer patients, *CASTRATION-resistant prostate cancer, *LINEAR energy transfer
Abstract

Background: Life expectancy of patients with metastatic castration-resistant prostate cancer (mCRPC) is still limited despite several systemic treatments. Within five years after diagnosis of primary prostate cancer, 10–20% of the patients have mCRPC and curation is not an option. Radionuclide therapy (RNT) targeted against prostate-specific membrane antigen (PSMA) emerged as a new treatment option and showed effective results in patients with mCRPC. Survival benefit after [177Lu]Lu-PSMA RNT has already been demonstrated in several clinical trials. However, [225Ac]Ac-PSMA (225Ac-PSMA) appears to be an even more promising radiopharmaceutical for the treatment of mCRPC. The use of alpha emitting radionuclides offers advantages over beta emitting radionuclides due to the high linear energy transfer effective for killing tumor cells and the limited range to reduce the radiation effects on the healthy tissue. However, these results are based on retrospective data and safety data of 225Ac-PSMA are still limited. Therefore, a prospective trial is needed to determine the optimal amount of activity that can be administered. Methods: The 225Ac-PSMA-Imaging & Therapy (I&T) trial is an investigator-initiated phase I, single-center, open label, repeated dose-escalation and expansion trial. Patient with PSMA-positive mCRPC after at least one line of chemotherapy and/or one line of nonsteroidal antiandrogen will be treated with 225Ac-PSMA-I&T in increasing amount of activity per cycle. Dose-escalation following an accelerated 3 + 3 design which allows to open the next dose-level cohort in the absence of dose limiting toxicity while the previous one is still ongoing. Up to 4 treatment cohorts will be explored including up to 3 dose-escalation cohorts and one expansion cohort where patients will be administered with the recommended dose. A total of up to 30 patients will be enrolled in this trial. All patients will be evaluated for safety. Additionally, dosimetry was performed for the patients in the dose-escalation cohorts after the first 225Ac-PSMA-I&T administration. Discussion: This trial will assess the safety and tolerability of 225Ac-PSMA-I&T in patients with mCRPC to recommend the optimal dose for the phase II trial. Trial registration: ClinicalTrials.gov, (NCT05902247). Retrospectively registered 13 June 2023. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma

Author

Verhoeff, Sarah R., van Es, Suzanne C., Boon, Eline, van Helden, Erik, Angus, Lindsay, Elias, Sjoerd G., Oosting, Sjoukje F., Aarntzen, Erik H., Brouwers, Adrienne H., Kwee, Thomas C., Heskamp, Sandra, Hoekstra, Otto S., Verheul, Henk, van der Veldt, Astrid A. M., de Vries, Elisabeth G. E., Boerman, Otto C., van der Graaf, Winette T. A., Oyen, Wim J. G., and van Herpen, Carla M. L.

Published
2019
Full Text
View/download PDF

31. COVID-19 vaccination: the VOICE for patients with cancer

Author

van der Veldt, Astrid A. M., Oosting, Sjoukje F., Dingemans, Anne-Marie C., Fehrmann, Rudolf S. N., GeurtsvanKessel, Corine, Jalving, Mathilde, Rimmelzwaan, Guus F., Kvistborg, Pia, Blank, Christian U., Smit, Egbert F., Lemmens, Valery E. E. P., Hiltermann, T. Jeroen N., Koopmans, Marion P. G., Huckriede, Anke L. W., Rots, Nynke Y., van Els, Cecile A. C. M., van Baarle, Debbie, Haanen, John B. A. G., and de Vries, Elisabeth G. E.

Published
2021
Full Text
View/download PDF

32. A Survival Tree of Advanced Melanoma Patients with Brain Metastases Treated with Immune Checkpoint Inhibitors

Author

van Not, Olivier J., primary, Wind, Thijs T., additional, Ismail, Rawa K., additional, Bhattacharya, Arkajyoti, additional, Jalving, Mathilde, additional, Blank, Christian U., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Boers-Sonderen, Marye J., additional, van den Eertwegh, Alfonsus J. M., additional, de Groot, Jan Willem B., additional, Haanen, John B., additional, Kapiteijn, Ellen, additional, Bloem, Manja, additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, Stevense-den Boer, Marion, additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, Wouters, Michel W. J. M., additional, Blokx, Willeke A. M., additional, Suijkerbuijk, Karijn P. M., additional, Fehrmann, Rudolf S. N., additional, and Hospers, Geke A. P., additional

Published
2023
Full Text
View/download PDF

36. Supplementary Figure 2 from Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status

Author

Bahce, Idris, primary, Smit, Egbert F., primary, Lubberink, Mark, primary, van der Veldt, Astrid A. M., primary, Yaqub, Maqsood, primary, Windhorst, Albert D., primary, Schuit, Robert C., primary, Thunnissen, Erik, primary, Heideman, Daniëlle A. M., primary, Postmus, Pieter E., primary, Lammertsma, Adriaan A., primary, and Hendrikse, N. Harry, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 1 from Development of [11C]erlotinib Positron Emission Tomography for In Vivo Evaluation of EGF Receptor Mutational Status

Author

Bahce, Idris, primary, Smit, Egbert F., primary, Lubberink, Mark, primary, van der Veldt, Astrid A. M., primary, Yaqub, Maqsood, primary, Windhorst, Albert D., primary, Schuit, Robert C., primary, Thunnissen, Erik, primary, Heideman, Daniëlle A. M., primary, Postmus, Pieter E., primary, Lammertsma, Adriaan A., primary, and Hendrikse, N. Harry, primary

Published
2023
Full Text
View/download PDF

38. Adjuvant treatment of in‐transit melanoma: Narrowing the knowledge gap left by clinical trials

Author

de Meza, Melissa M., primary, Blokx, Willeke A. M., additional, Bonenkamp, Han J., additional, Blank, Cristian U., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Boers‐Sonderen, Marye J., additional, de Groot, Jan Willem B., additional, Haanen, John B., additional, Hospers, Geke A. P., additional, Kapiteijn, Ellen W., additional, van Not, Olivier J., additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, Stevense‐Den Boer, Marion A., additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, van den Eertwegh, Alfons J. M., additional, Suijkerbuijk, Karijn P. M., additional, and Wouters, Michel W. J. M., additional

Published
2023
Full Text
View/download PDF

39. Time interval from primary melanoma to first distant recurrence in relation to patient outcomes in advanced melanoma

Author

van Duin, Isabella A. J., primary, Elias, Sjoerd G., additional, van den Eertwegh, Alfonsus J. M., additional, de Groot, Jan Willem B., additional, Blokx, Willeke A. M., additional, van Diest, Paul J., additional, Leiner, Tim, additional, Verhoeff, Joost J. C., additional, Verheijden, Rik J., additional, van Not, Olivier J., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Blank, Christian U., additional, Haanen, John B. A. G., additional, Hospers, Geke A. P., additional, Kamphuis, Anna M., additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, Wouters, Michel W. J. M., additional, Stevense‐den Boer, Marion A. M., additional, Boers‐Sonderen, Marye J., additional, Kapiteijn, Ellen, additional, and Suijkerbuijk, Karijn P. M., additional

Published
2023
Full Text
View/download PDF

40. Impact of Novel Treatments in Patients with Melanoma Brain Metastasis: Real-World Data

Author

Derks, Sophie H. A. E., primary, Jongen, Joost L. M., additional, van der Meer, Edgar L., additional, Ho, Li Shen, additional, Slagter, Cleo, additional, Joosse, Arjen, additional, de Jonge, Maja J. A., additional, Schouten, Joost W., additional, Oomen-de Hoop, Esther, additional, van den Bent, Martin J., additional, and van der Veldt, Astrid A. M., additional

Published
2023
Full Text
View/download PDF

42. Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis

Author

De Meza, Melissa M., primary, Blokx, Willeke A. M., additional, Bonenkamp, Johannes J., additional, Blank, Christian U., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Boers-Sonderen, Marye J., additional, De Groot, Jan Willem B., additional, Haanen, John B. A. G., additional, Hospers, Geke A. P., additional, Kapiteijn, Ellen, additional, Van Not, Olivier J., additional, Piersma, Djura, additional, Van Rijn, Rozemarijn S., additional, Stevense-den Boer, Marion, additional, Van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, Van den Eertwegh, Alfonsus J. M., additional, Suijkerbuijk, Karijn P. M., additional, and Wouters, Michel W. J. M., additional

Published
2023
Full Text
View/download PDF

43. Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAFV600-mutant advanced melanoma patients: a propensity-matched survival analysis

Author

van Breeschoten, Jesper, Wouters, Michel W. J. M., Hilarius, Doranne L., Haanen, John B., Blank, Christian U., Aarts, Maureen J. B., van den Berkmortel, Franchette W. P. J., de Groot, Jan-Willem B., Hospers, Geke A. P., Kapiteijn, Ellen, Piersma, Djura, van Rijn, Roos S., Suijkerbuijk, Karijn P. M., Blokx, Willeke A. M., ten Tije, Bert-Jan J., van der Veldt, Astrid A. M., Vreugdenhil, Art, Boers-Sonderen, Marye J., and van den Eertwegh, Alfonsus J. M.

Published
2021
Full Text
View/download PDF

47. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

Author

Hurkmans, Daan P., Basak, Edwin A., van Dijk, Tanja, Mercieca, Darlene, Schreurs, Marco W. J., Wijkhuijs, Annemarie J. M., Bins, Sander, Hoop, Esther Oomen-de, Debets, Reno, Joerger, Markus, Odink, Arlette, van der Veldt, Astrid A. M., van der Leest, Cor H., Aerts, Joachim G. J. V., Mathijssen, Ron H. J., and Koolen, Stijn L. W.

Published
2019
Full Text
View/download PDF

49. CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab

Author

Kunert, Andre, Basak, Edwin A., Hurkmans, Daan P., Balcioglu, Hayri E., Klaver, Yarne, van Brakel, Mandy, Oostvogels, Astrid A. M., Lamers, Cor H. J., Bins, Sander, Koolen, Stijn L. W., van der Veldt, Astrid A. M., Sleijfer, Stefan, Mathijssen, Ron H. J., Aerts, Joachim G. J. V., and Debets, Reno

Published
2019
Full Text
View/download PDF

50. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study

Author

van der Kooij, Monique K., primary, Joosse, Arjen, additional, Suijkerbuijk, Karijn P. M., additional, Aarts, Maureen J. B., additional, van den Berkmortel, Franchette W. P. J., additional, Blank, Christian U., additional, Boers-Sonderen, Marye J., additional, van den Eertwegh, Alfonsus J. M., additional, de Groot, Jan Willem B., additional, Haanen, John B. A. G., additional, Hospers, Geke A. P., additional, Piersma, Djura, additional, van Rijn, Rozemarijn S., additional, van der Veldt, Astrid A. M., additional, Vreugdenhil, Gerard, additional, Westgeest, Hans M., additional, Wouters, Michel W. J. M., additional, Dekkers, Olaf M., additional, and Kapiteijn, Ellen, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results